tiprankstipranks
Bristol-Myers Squibb Reports Strong Q3 2024 Results
Company Announcements

Bristol-Myers Squibb Reports Strong Q3 2024 Results

Don't Miss our Black Friday Offers:

Bristol-Myers Squibb ( (BMY) ) just unveiled an announcement.

Bristol Myers Squibb reported robust third-quarter results for 2024, with revenues rising to $11.9 billion, marking an 8% increase (10% when adjusted for foreign exchange). The company’s Growth Portfolio and U.S. approval of Cobenfy for schizophrenia played significant roles in this performance. Despite some challenges like generic erosion of Sprycel, the firm saw strong cash flow and increased revenue guidance. Investors should note the balance of GAAP and non-GAAP figures, reflecting strategic financial moves and a focus on sustainable growth.

For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBuy/Sell: Wall Street’s top 10 stock calls this week
TheFlyBristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy
TheFlyBristol Myers receives positive CHMP opinion for repotrectinib
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App